NEW YORK (GenomeWeb News) — Alnylam and Merck today said they have ended an ongoing RNAi drug-development alliance, and Alnylam has rescinded its IP grants related to any Merck development programs.
 
The deal was worth more than $120 million to Alnylam and ended on a mutually agreed upon note. The companies did not elaborate.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.